Issues related to CMS drug pricing, FDA drug regulations, biosimilar coverage and reimbursement
2026 · 3rd Quarter (July 1 - Sep 30)
CELLTRION USA, INC.
Filed by BLUEBIRD STRATEGIES.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 16, 2026
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- BLUEBIRD STRATEGIES
- Client
- CELLTRION USA, INC.
- Filing UUID
- fc01931f-a4e5-44c8-afa1-ba97ccdc369f
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.